A Comprehensive Clinical and Pharmacological Monograph of Levomilnacipran (Fetzima): An SNRI with a Unique Noradrenergic Profile

Executive Summary

Levomilnacipran, marketed under the brand name Fetzima, is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment of Major Depressive Disorder (MDD) in adults. It represents a "chiral switch" from its parent compound, milnacipran, being the more pharmacologically active (1S,2R)-enantiomer. This monograph provides an exhaustive analysis of Levomilnacipran's chemical properties, pharmacological mechanisms, pharmacokinetic profile, clinical trial evidence, safety and tolerability, and global regulatory status.

Pharmacologically, Levomilnacipran is distinguished from other SNRIs by its potent and preferential inhibition of norepinephrine reuptake over serotonin reuptake, with an approximate 1:2 inhibition ratio. This unique noradrenergic-dominant profile may confer therapeutic advantages for MDD symptoms such as fatigue and amotivation, but it is also directly responsible for its characteristic adverse effect profile, which is heavily skewed towards cardiovascular and genitourinary symptoms, including increased heart rate, elevated blood pressure, and urinary hesitation. Emerging preclinical data also identifies Levomilnacipran as an inhibitor of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), suggesting a potential, though unproven, role in modulating neurodegenerative processes associated with Alzheimer's disease.

The pharmacokinetic profile is characterized by high oral bioavailability (92%), low plasma protein binding (22%), and an elimination half-life of approximately 12 hours, which supports a once-daily extended-release formulation. Elimination is highly dependent on two key pathways: approximately 58% of the drug is excreted unchanged via the kidneys, and the remainder is metabolized primarily by the cytochrome P450 enzyme CYP3A4. This creates two critical points of vulnerability, necessitating mandatory dose adjustments in patients with renal impairment and in those taking strong CYP3A4 inhibitors.

Clinical efficacy in MDD was established in several short-term, placebo-controlled trials that demonstrated statistically significant improvements in both depressive symptoms (measured by the Montgomery–Åsberg Depression Rating Scale) and functional impairment (measured by the Sheehan Disability Scale). However, the clinical development program's reliance on placebo-controlled trials without an active comparator arm has led to divergent global regulatory outcomes. While approved by the U.S. Food and Drug Administration (FDA) and Health Canada, the application was rejected by Australia's Therapeutic Goods Administration (TGA) due to the absence of data comparing it to an established standard-of-care antidepressant.

The safety profile is well-defined, with the most common adverse events being nausea, constipation, hyperhidrosis, and cardiovascular effects. Levomilnacipran carries an FDA boxed warning for an increased risk of suicidal thoughts and behaviors in young adults, a class-wide warning for all antidepressants. Significant drug interactions, particularly with Monoamine Oxidase Inhibitors (MAOIs), other serotonergic agents, and drugs affecting hemostasis, require careful management. A critical interaction with alcohol can cause accelerated drug release ("dose dumping") from the extended-release formulation, increasing the risk of toxicity.

In conclusion, Levomilnacipran is a distinct pharmacological agent within the SNRI class with a clear mechanism of action and proven efficacy against placebo for MDD. Its place in therapy is likely as a second- or third-line agent, potentially for a subset of patients with a specific symptom profile. Its unique regulatory history underscores the increasing global demand for comparative effectiveness data. Future research should focus on head-to-head trials against other antidepressants and further exploration of its novel BACE-1 inhibitory properties.

Section 1: Introduction and Molecular Profile

1.1 Developmental History and Lineage from Milnacipran

Levomilnacipran is a second-generation antidepressant that emerged from the strategic pharmaceutical practice known as a "chiral switch".[1] It is the isolated levorotatory, or (1S,2R), enantiomer of the racemic compound milnacipran.[1] The parent drug, milnacipran, is a well-established serotonin-norepinephrine reuptake inhibitor (SNRI) with a long history of clinical use. While milnacipran is approved for the treatment of Major Depressive Disorder (MDD) in over 45 countries, including in Europe and Japan, its regulatory path in the United States was different; the U.S. Food and Drug Administration (FDA) approved it in 2009, under the brand name Savella, exclusively for the management of fibromyalgia.[5]

This regulatory divergence created a unique situation where a compound with known antidepressant efficacy abroad was not available for that indication in the large U.S. market. The development of Levomilnacipran by Pierre Fabre and Forest Laboratories was a direct strategy to address this. By isolating the (1S,2R)-enantiomer, which was identified as the more pharmacologically active component of the racemic mixture, the developers created a new chemical entity for regulatory purposes.[1] This approach aimed to leverage the known pharmacology and safety profile of the parent compound while potentially offering an improved therapeutic profile and simplified pharmacokinetics. A critical pharmacokinetic property is that in vivo interconversion between levomilnacipran and its dextrorotatory stereoisomer does not occur in humans, ensuring that the pharmacological activity observed is stable and attributable solely to the intended enantiomer.[1]

Following a dedicated clinical development program focused on MDD, Levomilnacipran received its first global approval from the US FDA on July 25, 2013, for the treatment of MDD in adults.[1] This successful navigation of the regulatory process effectively brought the antidepressant properties of the milnacipran pharmacophore to the U.S. market under a new name and with renewed patent protection.[13]

1.2 Chemical Identity and Physicochemical Properties

Levomilnacipran is classified as a small molecule therapeutic agent, identified by the DrugBank accession number DB08918.[1] Its chemical and physical identifiers are well-defined and are crucial for its characterization in research, manufacturing, and clinical settings.

The formal chemical name is (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide, with the International Union of Pure and Applied Chemistry (IUPAC) name specified as cis-(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide.[1] This nomenclature precisely describes the stereochemistry and functional groups attached to the core cyclopropane ring structure.

The Chemical Abstracts Service (CAS) Registry Number for the free base form of the molecule is 96847-54-0.[1] In its commercially available form, it is often formulated as a hydrochloride salt, which has the distinct CAS Number 175131-60-9.[2] The molecular formula for the free base is

, corresponding to a molecular weight of 246.35 g·mol⁻¹.[1] The compound is known by several synonyms, including L-Milnacipran, (1S-cis)-Milnacipran, and the developmental code F2695.[1] A summary of these key identifiers is provided in Table 1.

Table 1: Chemical and Physical Identifiers of Levomilnacipran

Identifier Type	Value	Source(s)
DrugBank ID	DB08918	1
Type	Small Molecule	1
IUPAC Name	cis-(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide	1
CAS Number (Free Base)	96847-54-0	1
CAS Number (HCl Salt)	175131-60-9	2
Molecular Formula		1
Molecular Weight	246.35 g·mol⁻¹	1
SMILES	CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2	1
InChI	InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1	1
InChIKey	GJJFMKBJSRMPLA-DZGCQCFKSA-N	1
Key Synonyms	L-Milnacipran, (1S-cis)-Milnacipran, Fetzima, F2695	2

1.3 Stereochemistry: The Significance of the (1S,2R)-Enantiomer

The defining chemical feature of Levomilnacipran is its specific stereochemistry. As the (1S,2R)-enantiomer of milnacipran, its three-dimensional structure is a mirror image of its dextrorotatory counterpart, (1R,2S)-milnacipran.[1] In pharmacology, such stereoisomers can have vastly different interactions with biological targets like receptors and transporters, which are themselves chiral. Levomilnacipran was specifically developed because the (1S,2R) configuration was determined to be the more pharmacologically potent component of the racemic milnacipran mixture.[1]

This stereospecificity is fundamental to its mechanism of action. The precise spatial arrangement of the aminomethyl group, the N,N-diethylcarboxamide group, and the phenyl group on the cyclopropane scaffold dictates its binding affinity and inhibitory potency at the serotonin and norepinephrine transporters. This structural specificity is captured and communicated through standardized chemical identifiers. The Simplified Molecular Input Line Entry System (SMILES) string, CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2, uses the "@" symbols to denote the specific chiral centers, ensuring the correct three-dimensional structure is represented.[1] Similarly, the International Chemical Identifier (InChI) and its condensed InChIKey provide a unique, unambiguous textual representation of the molecule's structure, including its stereochemistry.[1] The isolation of this single, more active enantiomer is intended to provide a more targeted pharmacological effect and a more predictable dose-response relationship compared to the racemic parent compound.

Section 2: Comprehensive Pharmacological Profile

2.1 Pharmacodynamics: Mechanism of Action

2.1.1 Dual Inhibition of Serotonin and Norepinephrine Transporters (SNRI)

The primary mechanism of action of Levomilnacipran, while not known with absolute certainty, is thought to be the potentiation of serotonergic and noradrenergic neurotransmission within the central nervous system (CNS).[1] This effect is achieved through high-affinity binding to and subsequent inhibition of the presynaptic reuptake transporters for serotonin (SERT) and norepinephrine (NET).[3] By blocking these transporters, Levomilnacipran decreases the clearance of serotonin (5-HT) and norepinephrine (NE) from the synaptic cleft, thereby increasing their availability to bind to postsynaptic receptors. This enhancement of monoaminergic signaling is the putative basis for its antidepressant effect.

In vitro binding assays have quantified its interaction with these transporters. Levomilnacipran binds with high affinity to both human SERT and NET, with reported binding affinity constants () of 11 nM and 91 nM, respectively.[3] It also potently inhibits the function of these transporters, with half maximal inhibitory concentration (

) values for reuptake inhibition reported as 16–19 nM for 5-HT and 11 nM for NE.[3] These values confirm its potent activity at both targets, firmly classifying it as an SNRI.

2.1.2 Comparative Receptor Binding Profile and Selectivity

A defining pharmacodynamic feature that distinguishes Levomilnacipran from other available SNRIs is its greater relative potency for norepinephrine reuptake inhibition compared to serotonin reuptake inhibition.[1] In vitro studies demonstrate that Levomilnacipran has an approximate 2-fold greater potency for inhibiting NE reuptake versus 5-HT reuptake.[23] This results in a serotonin-to-norepinephrine reuptake inhibition ratio of approximately 1:2.[2]

This noradrenergic-dominant, or "adrenergic," profile is unique among its class, as shown in Table 3. Other widely used SNRIs, such as venlafaxine, duloxetine, and desvenlafaxine, all exhibit a preference for serotonin reuptake inhibition.[2] This distinction has significant clinical implications. The enhanced noradrenergic activity of Levomilnacipran may be particularly beneficial for treating depressive symptoms associated with deficits in norepinephrine signaling, such as fatigue, apathy, and impaired concentration. However, this same mechanism is also the direct physiological driver of its most common and clinically relevant adverse effects. The potentiation of norepinephrine, a key neurotransmitter in the sympathetic nervous system, directly leads to increased heart rate, elevated blood pressure, excessive sweating (hyperhidrosis), and urinary hesitation—all of which are prominent in Levomilnacipran's side effect profile.[2] Thus, the drug's primary pharmacological characteristic is inextricably linked to both its potential therapeutic niche and its principal tolerability challenges.

Furthermore, Levomilnacipran exhibits high selectivity for its primary targets. It lacks significant binding affinity for a wide panel of over 23 off-target sites, including other neurotransmitter receptors (e.g., serotonergic 5HT₁₋₇, α- and β-adrenergic, muscarinic, histaminergic) and various ion channels.[2] This "clean" receptor profile means it is less likely to cause side effects commonly associated with older antidepressants that bind to these other receptors, such as the sedation from antihistaminic activity or the dry mouth and constipation from anticholinergic activity. While some studies have noted a weak affinity for the NMDA receptor at high concentrations, suggesting a potential antagonist effect, the clinical relevance of this finding remains unclear.[2]

Table 3: Comparative Pharmacodynamic Profile of Common SNRIs

Drug	Serotonin:Norepinephrine Reuptake Inhibition Ratio	Primary Clinical Implications	Source(s)
Levomilnacipran	1:2	Potent noradrenergic activity; may be beneficial for fatigue/amotivation but higher risk of cardiovascular side effects.	2
Milnacipran	1:1.6	Balanced activity, similar to Levomilnacipran but less NE-dominant.	2
Desvenlafaxine	14:1	Predominantly serotonergic activity.	2
Duloxetine	10:1	Predominantly serotonergic activity.	2
Venlafaxine	30:1	Highly serotonergic at lower doses, with noradrenergic effects emerging at higher doses.	2

2.1.3 Novel Mechanisms: BACE-1 Inhibition and Implications for Neurodegenerative Disease

Beyond its established role as an SNRI, emerging preclinical research has identified a novel and potentially significant secondary mechanism of action for Levomilnacipran: the inhibition of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1).[2] BACE-1 is the rate-limiting enzyme in the amyloidogenic pathway, responsible for the initial cleavage of the amyloid precursor protein (APP). This cleavage is a critical step in the formation of amyloid-beta (Aβ) peptides, which aggregate to form the amyloid plaques that are a neuropathological hallmark of Alzheimer's disease (AD).[28]

Molecular docking studies have shown that Levomilnacipran interacts with key catalytic aspartic acid residues (D32 and D228) in the active site of BACE-1, suggesting a plausible mechanism for its inhibitory activity.[28] The free energy of binding for the Levomilnacipran-BACE1 interaction was calculated to be -8.25 kcal/mol, indicating a favorable interaction.[28]

This discovery carries profound implications that extend beyond the treatment of depression. It is well-established that MDD is a significant risk factor for the later development of AD, though the underlying biological link remains poorly understood.[28] The finding that a single molecule can inhibit both SERT (a key target in depression) and BACE-1 (a key target in AD) suggests a potential mechanistic bridge between these two disorders. This dual activity positions Levomilnacipran as a compelling candidate for future research into drug repurposing. It raises critical questions for the field: Could the BACE-1 inhibitory action contribute to Levomilnacipran's antidepressant effects? More importantly, could long-term treatment of depression with this specific agent confer a neuroprotective benefit by reducing Aβ production and potentially modifying the risk or progression of AD? While currently speculative, this finding opens a new avenue of investigation into the complex interplay between mood disorders and neurodegeneration.

2.2 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Levomilnacipran dictates its dosing regimen, potential for drug interactions, and requirements for dose adjustments in specific patient populations. It is characterized by good absorption, wide distribution, metabolism primarily via a single major enzyme pathway, and significant renal excretion of the parent drug. A summary of key parameters is provided in Table 2.

2.2.1 Absorption and Distribution

Levomilnacipran is formulated for clinical use in an extended-release (ER) capsule, which is designed to allow for convenient once-daily administration.[5] Following oral administration, the drug is well absorbed, exhibiting a high absolute bioavailability of 92% when compared to an oral solution.[2] The absorption is not significantly affected by the presence of food, allowing for flexible administration with or without meals.[3] Due to the extended-release formulation, the time to reach peak plasma concentration (

) is delayed, typically occurring between 6 and 8 hours post-dose.[3]

Once absorbed, Levomilnacipran is widely distributed throughout the body, as indicated by its large apparent volume of distribution (), which ranges from 387 to 473 L.[3] This suggests extensive distribution into tissues outside of the plasma. Plasma protein binding is low, at approximately 22% over a wide concentration range.[2] This low level of protein binding minimizes the risk of clinically significant drug-drug interactions resulting from displacement of other highly protein-bound drugs from plasma proteins.

2.2.2 Metabolism

Levomilnacipran undergoes hepatic metabolism, primarily catalyzed by the cytochrome P450 (CYP) enzyme system.[2] The principal enzyme responsible for its biotransformation is

CYP3A4.[2] Several other CYP isoforms, including CYP2C8, CYP2C19, CYP2D6, and CYP2J2, make minor contributions to its metabolism.[3] The heavy reliance on a single major enzyme, CYP3A4, makes Levomilnacipran susceptible to pharmacokinetic interactions with drugs that are strong inhibitors or inducers of this enzyme.

The main metabolic pathways are oxidative and involve desethylation to form N-desethyl levomilnacipran and hydroxylation to form p-hydroxy-levomilnacipran.[3] Both of these primary metabolites are considered pharmacologically inactive. They can undergo subsequent Phase II metabolism via glucuronidation to form more water-soluble conjugates that are readily excreted.[3] In urine, the major metabolite recovered is N-desethyl levomilnacipran, which accounts for approximately 18% of the administered dose.[3]

2.2.3 Elimination

The primary route of elimination for Levomilnacipran and its metabolites is renal excretion.[2] A human mass balance study using radiolabeled Levomilnacipran found that a substantial portion of the drug, approximately 58%, is excreted in the urine as unchanged, parent compound.[3] This high degree of renal clearance of the active drug is a critical pharmacokinetic feature. The apparent terminal elimination half-life (

) of the extended-release formulation is approximately 12 hours, a duration that supports the once-daily dosing regimen.[2] The pharmacokinetics are linear and dose-proportional across the clinically recommended dose range of 25 to 300 mg per day, meaning that steady-state concentrations are predictable from single-dose data.[3]

The significant reliance on renal excretion makes the drug's pharmacokinetics highly sensitive to changes in kidney function. In patients with renal impairment, the clearance of Levomilnacipran is significantly reduced, leading to prolonged half-life and increased systemic exposure (Area Under the Curve, or AUC).[22] For example, studies have shown that the mean elimination half-life increases from 13.5 hours in individuals with normal renal function to 19.1 hours in those with moderate impairment and up to 27.7 hours in those with severe impairment.[22] This direct and quantifiable relationship between declining renal function and increased drug exposure is the basis for the mandatory dosage adjustments required for patients with moderate to severe renal impairment, a crucial aspect of safe prescribing.[9] The combination of a high degree of renal excretion of the parent drug and metabolism via a single dominant CYP enzyme creates two distinct points of vulnerability for altered drug exposure, complicating its use in patients with renal disease or those on common interacting medications.

Table 2: Summary of Levomilnacipran Pharmacokinetic Parameters in Adults

Parameter	Value	Source(s)
Bioavailability	92%	2
Time to Peak Concentration ()	6–8 hours	3
Volume of Distribution ()	387–473 L	3
Plasma Protein Binding	22%	2
Elimination Half-Life ()	~12 hours	2
Primary Metabolic Enzyme	CYP3A4	2
Major Metabolite	N-desethyl levomilnacipran	3
Primary Excretion Route	Renal	2
% Excreted Unchanged in Urine	~58%	3

Section 3: Clinical Efficacy and Therapeutic Use

3.1 Approved Indication: Major Depressive Disorder (MDD)

Levomilnacipran, marketed as Fetzima, is officially indicated by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD) in adult patients.[1] Its approval for this indication was the culmination of a comprehensive clinical development program designed to establish its efficacy and safety specifically for this patient population. The program included a total of five pivotal short-term studies: one Phase II dose-finding study and four larger Phase III randomized, double-blind, placebo-controlled trials.[2] These core studies were conducted in adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for MDD. The trials typically had a duration of 8 to 10 weeks and evaluated the efficacy of once-daily doses of Levomilnacipran ranging from 40 mg to 120 mg.[2]

3.2 Analysis of Pivotal Trial Efficacy Outcomes

Across the pivotal clinical trials, Levomilnacipran consistently demonstrated statistically significant superiority over placebo in the primary and key secondary efficacy measures.[2]

The primary efficacy endpoint in these studies was the change from baseline to the end of the study (typically week 8 or 10) in the total score of the Montgomery–Åsberg Depression Rating Scale (MADRS), a standard clinician-rated scale for assessing the severity of depressive symptoms. In a representative Phase III study, all tested doses of Levomilnacipran (40 mg, 80 mg, and 120 mg) showed a significantly greater reduction in MADRS total score compared to placebo. The least squares mean difference (LSMD) versus placebo was -3.23 for the 40 mg dose, -3.99 for the 80 mg dose, and -4.86 for the 120 mg dose, indicating a robust and dose-related treatment effect.[23] Similar positive outcomes were observed in other trials within the development program.[6]

A particularly important secondary outcome was the effect of Levomilnacipran on functional impairment, a core component of disability in MDD that affects a patient's ability to engage in work, social life, and family responsibilities. This was assessed using the Sheehan Disability Scale (SDS). Levomilnacipran demonstrated statistically significant superiority to placebo in improving the SDS total score, with significant LSMDs observed for the 80 mg and 120 mg doses.[2] This finding is noteworthy because it suggests that the therapeutic benefit of Levomilnacipran extends beyond mood improvement to the restoration of daily functioning, a critical goal of antidepressant treatment.[9] Other secondary measures, including response rates (defined as a ≥50% reduction in MADRS score) and remission rates (defined as a MADRS total score ≤10), were also significantly higher in patients treated with Levomilnacipran compared to those receiving placebo.[8] A summary of key efficacy outcomes from a pivotal trial is presented in Table 4.

Table 4: Key Efficacy Outcomes from a Pivotal Phase III MDD Trial (NCT00969709)

Dose(s) Studied	Primary Outcome (MADRS LSMD vs. Placebo)	Key Secondary Outcome (SDS LSMD vs. Placebo)	Source(s)
40 mg/day	-3.23 ()	Not statistically significant	23
80 mg/day	-3.99 ()	-2.51 ()	23
120 mg/day	-4.86 ()	-2.57 ()	23
LSMD = Least Squares Mean Difference; MADRS = Montgomery–Åsberg Depression Rating Scale; SDS = Sheehan Disability Scale

Despite these positive results against placebo, a critical analysis of the trial design reveals a significant limitation that has had major regulatory consequences. The pivotal studies submitted for registration lacked an active comparator arm.[36] This means that while Levomilnacipran was proven to be more effective than no treatment, its efficacy relative to existing, standard-of-care antidepressants (e.g., other SNRIs or SSRIs) was not established in these core trials. This absence of comparative data makes it difficult to ascertain the drug's true place in the therapeutic armamentarium. While sufficient for FDA approval, which primarily requires superiority over placebo, this methodological choice was deemed insufficient by other regulatory bodies, such as Australia's TGA, which require new drugs to be benchmarked against accepted standard treatments.[36] This context reframes the efficacy data: Levomilnacipran is an effective antidepressant, but its superiority or even non-inferiority to other widely used agents remains unproven by its registration trials, positioning it as a second-line option for many clinicians.[5]

3.3 Long-Term Efficacy and Relapse Prevention

The assessment of an antidepressant's utility must extend beyond short-term symptom reduction to its ability to maintain response and prevent relapse over the long term. The long-term profile of Levomilnacipran has been evaluated in open-label extension studies, with some patients followed for up to 48 weeks.[37] These studies have provided valuable data on the long-term safety and tolerability of the drug.

However, the evidence base for long-term efficacy in preventing relapse is less robust. One long-term, placebo-controlled study designed to evaluate relapse prevention did not demonstrate a statistically significant superiority for Levomilnacipran over placebo.[9] Recognizing this gap in the data, the FDA, as a condition of Levomilnacipran's approval, required the sponsor to conduct an additional post-marketing study to more definitively evaluate its long-term maintenance efficacy. This study was designed as a placebo-controlled, randomized withdrawal trial, with a final report due to the FDA in 2019.[38] The results of such studies are critical for confirming the drug's role in the continuation and maintenance phases of MDD treatment.

3.4 Documented Off-Label and Investigational Uses

While Levomilnacipran is only officially approved for MDD, its pharmacological profile as an SNRI has led to its off-label use for a variety of other conditions.[5] These uses are often extrapolated from the established indications of its parent compound, milnacipran, and other drugs in the SNRI class, which have proven efficacy in pain and anxiety disorders.

Documented off-label applications for Levomilnacipran include the management of fibromyalgia, various anxiety disorders, vasomotor symptoms associated with menopause, diabetic peripheral neuropathy, and chronic musculoskeletal pain.[5] It is important to note that the efficacy and safety of Levomilnacipran for these conditions have not been established through rigorous, controlled clinical trials, and its use remains off-label.

In addition to these off-label uses, Levomilnacipran was formally investigated in Europe as a potential treatment to improve functional recovery in patients following an ischemic stroke.[1] However, this line of investigation did not lead to an approval, as the European Medicines Agency (EMA) ultimately issued a negative decision for this indication.[1]

Section 4: Safety, Tolerability, and Risk Management

4.1 The FDA Black Box Warning: Suicidality Risk

In line with all antidepressant medications approved in the United States, Levomilnacipran carries a prominent boxed warning—the most serious type of warning issued by the FDA—regarding the risk of suicidal thoughts and behaviors.[25] Pooled analyses of short-term, placebo-controlled trials have shown that antidepressants increase this risk in children, adolescents, and young adults (ages 18–24) compared to placebo.[40] The risk was not seen in adults older than 24, and a decreased risk was observed in adults aged 65 and older.[40]

It is critical to note that Levomilnacipran is not approved for use in any pediatric population.[21] The warning emphasizes that all patients, regardless of age, who are started on antidepressant therapy should be monitored closely for signs of clinical worsening, the emergence of suicidal ideation, or unusual changes in behavior. These changes can include anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, and impulsivity.[40] This heightened monitoring is especially crucial during the initial few months of treatment and whenever the dosage is adjusted. Prescribers are instructed to counsel patients, their families, and caregivers about this risk and the importance of reporting any concerning changes in behavior to the healthcare provider immediately.[40]

4.2 Common and Dose-Related Adverse Events

The tolerability profile of Levomilnacipran is largely predictable based on its potent noradrenergic mechanism of action. The most frequently reported adverse reactions, defined as those occurring at an incidence of ≥5% and at least twice the rate of placebo in short-term clinical trials, are nausea, constipation, hyperhidrosis (excessive sweating), increased heart rate, erectile dysfunction, ejaculation disorder, tachycardia, vomiting, and palpitations.[2]

Nausea is the most common side effect, reported in up to 17% of patients, and is also the single most common adverse reaction leading to treatment discontinuation, accounting for 1.5% of dropouts in clinical trials.[2] Overall, approximately 9% of patients treated with Levomilnacipran discontinued treatment due to an adverse event, compared to 3% of patients in the placebo group.[9]

Certain adverse effects have demonstrated a clear dose-dependent relationship. Specifically, the incidence of urinary hesitation and erectile dysfunction increases as the dose of Levomilnacipran is raised from 40 mg to 120 mg per day.[5] A summary of the incidence of the most common adverse reactions is provided in Table 5.

Table 5: Incidence of Common Adverse Reactions (≥5% and at least twice the rate of placebo)

Adverse Reaction	Levomilnacipran (40–120 mg) % Incidence	Placebo % Incidence	Source(s)
Nausea	17%	7%	2
Constipation	9%	3%	2
Hyperhidrosis	9%	2%	25
Heart Rate Increased	6%	1%	27
Erectile Dysfunction	6%	1%	25
Tachycardia	5%	1%	2
Vomiting	5%	1%	2
Palpitations	5%	1%	2

4.3 Serious Adverse Events and Special Warnings

Beyond the common side effects, Levomilnacipran is associated with several potentially serious risks that require careful patient selection and monitoring. These risks are detailed in the "Warnings and Precautions" section of the prescribing information and are largely a direct clinical manifestation of the drug's potent noradrenergic and serotonergic activity.

4.3.1 Serotonin Syndrome

A potentially life-threatening condition, serotonin syndrome can result from excessive serotonergic activity in the CNS. The risk is highest when Levomilnacipran is co-administered with other serotonergic agents, such as Monoamine Oxidase Inhibitors (MAOIs), triptans, tricyclic antidepressants, fentanyl, tramadol, lithium, buspirone, and the herbal supplement St. John's Wort.[25] Symptoms are wide-ranging and include mental status changes (e.g., agitation, confusion, delirium), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia, diaphoresis), and neuromuscular hyperactivity (e.g., tremor, myoclonus, rigidity).[41] Due to this risk, the concurrent use of Levomilnacipran with MAOIs is strictly contraindicated.[43]

4.3.2 Cardiovascular Effects

Given its potent inhibition of norepinephrine reuptake, Levomilnacipran can cause clinically significant elevations in both blood pressure and heart rate.[25] In clinical trials, treatment was associated with a median increase in systolic and diastolic blood pressure of 4 mm Hg and 2.5 mm Hg, respectively.[25] It is recommended that pre-existing hypertension be controlled before initiating therapy, and both blood pressure and heart rate should be monitored regularly throughout treatment.[8] The drug is contraindicated in patients with uncontrolled hypertension, a recent myocardial infarction, or other serious, unstable cardiac conditions.[44]

4.3.3 Genitourinary Effects

Noradrenergic effects on the urinary system can lead to urinary hesitation or retention, which may be severe enough to require discontinuation of the drug.[2] Sexual dysfunction is also a common and often distressing side effect. In male patients, this can manifest as erectile dysfunction, ejaculation disorder (including delay or failure), and decreased libido. In female patients, it can cause decreased libido and delayed or absent orgasm.[2]

4.3.4 Other Significant Risks

• Abnormal Bleeding: SNRIs can affect platelet function, leading to an increased risk of bleeding events, ranging from bruising and nosebleeds to more serious gastrointestinal hemorrhage. This risk is potentiated by the concurrent use of medications that interfere with hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and anticoagulants like warfarin.[27]
• Activation of Mania/Hypomania: In patients with underlying bipolar disorder, antidepressants can trigger a switch into mania or hypomania. Therefore, all patients should be screened for a personal or family history of bipolar disorder before starting Levomilnacipran.[27]
• Seizures: Seizures have been reported with Levomilnacipran. The drug should be used with caution in patients with a history of seizure disorders.[27]
• Hyponatremia: Clinically significant hyponatremia (low sodium in the blood), likely due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), can occur. Elderly patients, those taking diuretics, and individuals who are volume-depleted are at higher risk.[21]
• Angle-Closure Glaucoma: The mydriatic (pupil-dilating) effect that can occur with antidepressants may trigger an angle-closure attack in patients with anatomically narrow angles who have not had a preemptive iridectomy.[27]
• Hepatotoxicity: While rare, Levomilnacipran has been associated with a low rate of transient, asymptomatic elevations in serum aminotransferase levels. There have been very rare reports of clinically apparent acute liver injury with its parent compound, milnacipran.[29]

4.4 Contraindications and Use in Specific Populations

The use of Levomilnacipran is strictly contraindicated in several situations due to the risk of severe adverse reactions. The primary contraindications are:

1. Known hypersensitivity to levomilnacipran, milnacipran hydrochloride, or any of the excipients in the formulation.[40]
2. Concurrent use with Monoamine Oxidase Inhibitors (MAOIs) intended to treat psychiatric disorders, or use within 14 days of discontinuing an MAOI or within 7 days of discontinuing Levomilnacipran. This is due to the high risk of life-threatening serotonin syndrome.[40]
3. Initiation of treatment in a patient who is currently being treated with other MAOIs, such as the antibiotic linezolid or intravenous methylene blue.[40]

Regarding specific populations:

• Lactation: Levomilnacipran itself has not been adequately studied in nursing mothers. However, data from its racemic parent, milnacipran, show that it is excreted into breastmilk at low levels, with an estimated relative infant dose of 2.8%. While adverse effects in breastfed infants are not expected, caution is advised, especially when nursing a newborn or preterm infant. Monitoring the infant for agitation, poor feeding, and poor weight gain is recommended.[16]
• Geriatric Use: Clinical studies have not identified specific problems that would limit its usefulness in the elderly. However, this population is more susceptible to certain side effects, particularly hyponatremia. Furthermore, age-related decline in renal function is common, which may necessitate dosage adjustments due to the drug's significant renal clearance pathway.[21]

Section 5: Prescribing Information and Clinical Practice

5.1 Dosage, Titration, and Administration Guidelines

Effective and safe use of Levomilnacipran requires adherence to specific guidelines for dosing, titration, and administration, as well as adjustments for certain patient populations.

• Formulation: Levomilnacipran is available as extended-release (ER) capsules, which are formulated for once-daily dosing. The available strengths are 20 mg, 40 mg, 80 mg, and 120 mg.[5]
• Initial Dosing and Titration: Treatment should be initiated at a dose of 20 mg once daily for the first two days. This initial low dose helps to improve tolerability, particularly for side effects like nausea. After two days, the dose should be increased to 40 mg once daily. Based on the patient's clinical response and tolerability, the dose may be further increased in increments of 40 mg at intervals of two or more days.[6]
• Maintenance and Maximum Dose: The recommended therapeutic dosage range for maintenance treatment is 40 mg to 120 mg once daily. The maximum recommended daily dose is 120 mg.[21] The appropriate dose should be determined by periodically reassessing the patient to determine the ongoing need for treatment and the optimal dosage.[32]
• Administration: The ER capsules should be taken once daily at approximately the same time each day to maintain consistent plasma concentrations. They can be taken with or without food. It is crucial that the capsules are swallowed whole; they must not be opened, chewed, or crushed, as this would disrupt the extended-release mechanism, leading to rapid drug release and an increased risk of adverse effects.[25]

5.2 Management of Clinically Significant Drug-Drug Interactions

Levomilnacipran is subject to numerous drug-drug interactions, with over 370 documented, of which more than 115 are classified as major.[46] These interactions are primarily driven by its pharmacodynamic effects on serotonin and norepinephrine and its pharmacokinetic metabolism via CYP3A4.

5.2.1 MAOIs and Other Serotonergic Agents

• Monoamine Oxidase Inhibitors (MAOIs): The co-administration of Levomilnacipran with MAOIs intended to treat psychiatric disorders (e.g., phenelzine, tranylcypromine) is absolutely contraindicated due to the high risk of inducing a life-threatening serotonin syndrome.[30] Strict washout periods are mandatory: at least 14 days must elapse after discontinuing an MAOI before starting Levomilnacipran, and conversely, at least 7 days must pass after stopping Levomilnacipran before initiating an MAOI.[21]
• Other Serotonergic Drugs: Caution and close monitoring for symptoms of serotonin syndrome are required when Levomilnacipran is used concurrently with other drugs that increase serotonin levels. This includes other antidepressants (SSRIs, TCAs), triptans used for migraines, the opioid analgesics tramadol and fentanyl, buspirone, and St. John's wort.[21]

5.2.2 CYP3A4 Inhibitors and Inducers

• Strong CYP3A4 Inhibitors: Since Levomilnacipran is primarily metabolized by CYP3A4, co-administration with strong inhibitors of this enzyme (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) will increase plasma concentrations of Levomilnacipran, raising the risk of adverse effects. When used with a strong CYP3A4 inhibitor, the maximum recommended daily dose of Levomilnacipran must be reduced to 80 mg.[8]
• Strong CYP3A4 Inducers: Conversely, co-administration with strong CYP3A4 inducers (e.g., carbamazepine, rifampin, apalutamide) can increase the metabolism of Levomilnacipran, leading to lower plasma concentrations and a potential reduction in therapeutic efficacy.[30]

5.2.3 Drugs Affecting Hemostasis (Anticoagulants and NSAIDs)

Levomilnacipran, like other SNRIs, can impair platelet aggregation. Therefore, concurrent use with drugs that also interfere with hemostasis significantly increases the risk of bleeding events. Patients should be cautioned about this risk when taking Levomilnacipran with NSAIDs (e.g., ibuprofen, naproxen), aspirin, warfarin, or other anticoagulants.[3]

5.2.4 The Critical Interaction with Alcohol

The interaction between Levomilnacipran and alcohol is particularly critical and extends beyond the typical warning about additive CNS depressant effects. Concurrent use of alcohol is contraindicated or strongly discouraged because it can compromise the integrity of the extended-release formulation.[30] Alcohol can cause an accelerated release of the drug from the capsule, a phenomenon known as "dose dumping".[30] This leads to a rapid and unintended spike in plasma drug concentration, which can significantly increase the risk of acute toxicity and severe adverse effects. This is a pharmacokinetic interaction related to the drug delivery system itself and represents a significant safety concern that must be clearly communicated to all patients.

Table 6: Dosage Adjustment Guidelines for Renal Impairment and Concomitant CYP3A4 Inhibitors

Condition	Parameter	Maximum Recommended Daily Dose	Source(s)
Normal Renal Function	CrCl ≥ 90 mL/min	120 mg	31
Mild Renal Impairment	CrCl 60–89 mL/min	120 mg (No adjustment needed)	30
Moderate Renal Impairment	CrCl 30–59 mL/min	80 mg	9
Severe Renal Impairment	CrCl 15–29 mL/min	40 mg	9
End-Stage Renal Disease (ESRD)	CrCl < 15 mL/min	Not Recommended	9
Drug Interaction	Co-administration with Strong CYP3A4 Inhibitor	80 mg	25
CrCl = Creatinine Clearance

5.3 Discontinuation Strategy and Management of Withdrawal Syndrome

As with all serotonergic antidepressants, abrupt cessation of Levomilnacipran treatment should be avoided to prevent the onset of a discontinuation (or withdrawal) syndrome.[31] A gradual dose reduction, or tapering, is recommended whenever possible to allow the nervous system to adapt to the absence of the drug.[27]

Symptoms of discontinuation syndrome can include a range of physical and psychological effects, such as dizziness, nausea, vomiting, headache, irritability, agitation, anxiety, paresthesias ("pins and needles" sensations), and nightmares.[26] If these symptoms become intolerable during the tapering process or after discontinuation, the prescriber should consider resuming the previously prescribed dose and then proceeding with a more gradual dose reduction schedule.[27] Patients should be advised not to stop the medication suddenly and to follow their prescriber's instructions for tapering.[32]

Section 6: Global Regulatory Landscape and Comparative Analysis

6.1 Regulatory Approvals: FDA and Health Canada

The regulatory journey of Levomilnacipran has been primarily focused on North America. The United States Food and Drug Administration (FDA) granted its approval on July 25, 2013, for the treatment of Major Depressive Disorder in adults, where it is marketed under the brand name Fetzima.[1] The FDA's decision was based on a review of the clinical trial data which demonstrated the drug's efficacy as being superior to placebo in short-term studies.[6] Following the U.S. approval, Health Canada also approved Levomilnacipran for the same indication on May 8, 2015.[38]

6.2 Regulatory Rejection: Analysis of the TGA's Decision

In a significant divergence from the North American decisions, the application to register Levomilnacipran (Fetzima) in Australia was rejected by the Therapeutic Goods Administration (TGA). The rejection occurred in July 2016, with the final public assessment report published in December 2016.[36]

The primary basis for the TGA's rejection was a critical aspect of the clinical trial design: the absence of an active comparator arm in the pivotal studies submitted for registration.[36] The TGA, often aligning its standards with those of the European Medicines Agency (EMA), maintains that for a new antidepressant to be approved, its efficacy and safety must be contextualized by comparing it not only to a placebo but also to an established standard-of-care treatment. This is to ensure that a new drug offers a meaningful benefit and a favorable risk-benefit profile relative to therapies that are already available to patients. The TGA Delegate concluded that because the pivotal studies lacked an active control, their internal validity was questionable, and therefore the results, while statistically significant against placebo, might not be clinically meaningful in the broader context of MDD treatment.[36]

This split regulatory decision serves as a powerful real-world illustration of the differing philosophies on what constitutes sufficient evidence for market approval. The FDA's approval confirms the drug's efficacy—its ability to produce a desired effect in a controlled clinical trial setting. The TGA's rejection, however, highlights a failure to demonstrate comparative effectiveness—its value and utility in relation to existing alternatives in real-world practice. This divergence underscores a growing global emphasis on comparative data and has significant implications for future drug development strategies, signaling to manufacturers that placebo-controlled data alone may no longer be sufficient for approval in all major markets.

6.3 Status with the European Medicines Agency (EMA)

Despite the long history of its parent compound, milnacipran, being used for depression in several European countries, a formal submission for the approval of Levomilnacipran for MDD has not been made to the European Medicines Agency (EMA).[38] The EMA did review Levomilnacipran for a different indication—improving functional recovery after stroke—but ultimately decided against this use, issuing a refusal.[1] The reasons for not pursuing an MDD indication in the EU are not publicly detailed but may be related to the high evidentiary standards, including the likely requirement for active comparator trials, which, as seen with the TGA, the initial development program did not include.

6.4 Comparative Positioning Against Other SNRIs

Levomilnacipran's place within the SNRI class is defined by its unique pharmacodynamic profile. Its primary differentiator is its potent, norepinephrine-dominant activity, with a serotonin-to-norepinephrine reuptake inhibition ratio of approximately 1:2.[2] This contrasts sharply with the more serotonergic profiles of other leading SNRIs like venlafaxine (30:1), duloxetine (10:1), and desvenlafaxine (14:1).[2]

This distinction forms the basis of its potential therapeutic niche. Theoretically, its strong noradrenergic effects may be particularly beneficial for patients whose depression is characterized by symptoms of fatigue, low energy, amotivation, and cognitive deficits ("brain fog").[5] However, this potential benefit is directly counterbalanced by a higher incidence of noradrenergic side effects, such as increased heart rate, elevated blood pressure, hyperhidrosis, and urinary hesitation.[5]

In clinical practice, Levomilnacipran is often considered a second-line SNRI.[5] This positioning is due to several factors: the lack of head-to-head clinical trial data demonstrating superiority or even non-inferiority to more established agents; a side effect profile that may be less tolerable for some patients compared to more serotonergic options; and a significantly higher cost compared to generic alternatives like venlafaxine and duloxetine.[25] Therefore, it is typically reserved for patients who have not responded to or tolerated other first-line antidepressant treatments.

Section 7: Conclusion and Future Perspectives

7.1 Summary of Levomilnacipran's Clinical Profile and Therapeutic Niche

Levomilnacipran (Fetzima) is a pharmacologically distinct member of the serotonin-norepinephrine reuptake inhibitor class, defined by its stereospecific nature as the (1S,2R)-enantiomer of milnacipran and its unique, potent, and preferential inhibition of norepinephrine reuptake. Its development and approval in the United States for Major Depressive Disorder addressed a market gap left by its parent compound, which was only approved for fibromyalgia in the U.S.

The clinical evidence has established its efficacy over placebo in the short-term treatment of MDD, demonstrating improvements in both core depressive symptoms and functional impairment. This suggests a comprehensive therapeutic effect. The potential therapeutic niche for Levomilnacipran may reside in the treatment of a subset of depressed patients whose symptom cluster is dominated by fatigue, apathy, and cognitive slowing—symptoms theoretically more responsive to enhanced noradrenergic neurotransmission.

However, this potential benefit is intrinsically linked to its primary limitations. The strong noradrenergic activity is the direct cause of a predictable and often burdensome adverse effect profile, characterized by cardiovascular stimulation (tachycardia, hypertension) and genitourinary symptoms (urinary hesitation, sexual dysfunction). Furthermore, its clinical utility is clouded by the absence of robust, long-term relapse prevention data and a lack of head-to-head trials comparing it to first-line antidepressants. Combined with its higher cost relative to generic SNRIs, its place in clinical practice is appropriately that of a second- or third-line agent, considered for patients who have failed to respond to or tolerate other treatments. Its divergent global regulatory history highlights the critical importance of comparative effectiveness data in modern drug approval.

7.2 Unanswered Questions and Future Research Directions

Despite its well-characterized profile, several critical questions about Levomilnacipran remain unanswered, pointing to clear directions for future research.

• Comparative Efficacy and Effectiveness: The most significant evidence gap is the lack of large-scale, randomized, double-blind, head-to-head clinical trials comparing Levomilnacipran with other first-line antidepressants, particularly other SNRIs like venlafaxine and duloxetine. Such studies are essential to definitively establish its relative efficacy, tolerability, and overall place in evidence-based treatment algorithms for MDD.
• Identification of Predictive Biomarkers: Research is needed to move beyond a theoretical understanding of its niche. Future studies should aim to identify clinical or biological markers that can predict which patients are most likely to respond favorably to Levomilnacipran's norepinephrine-dominant mechanism. This could involve stratifying patients by baseline symptoms (e.g., high vs. low fatigue) or exploring genetic or neuroimaging biomarkers related to the noradrenergic system.
• Elucidation of the BACE-1 Inhibition Mechanism: The preclinical finding of BACE-1 inhibition is a compelling discovery that warrants significant further investigation. The immediate next steps should include confirming this activity in more advanced in vitro and in vivo models. Ultimately, prospective clinical studies are needed to determine if long-term treatment with Levomilnacipran has any measurable effect on cognitive function, cerebrospinal fluid biomarkers of amyloid processing, or the long-term risk of developing neurodegenerative diseases like Alzheimer's in patients with MDD.
• Validation of Off-Label Uses: The current off-label use of Levomilnacipran for conditions like fibromyalgia, neuropathic pain, and anxiety disorders is based on extrapolation rather than direct evidence. Rigorous, placebo-controlled, and active-comparator-controlled trials are required to formally evaluate its efficacy and safety in these patient populations to determine if these uses are justified.

Works cited

1. Levomilnacipran | C15H22N2O | CID 6917779 - PubChem, accessed October 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Levomilnacipran
2. Levomilnacipran - Wikipedia, accessed October 2, 2025, https://en.wikipedia.org/wiki/Levomilnacipran
3. Levomilnacipran: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 2, 2025, https://go.drugbank.com/drugs/DB08918
4. Levomilnacipran hydrochloride | DrugBank Online, accessed October 2, 2025, https://go.drugbank.com/salts/DBSALT000107
5. LEVOMILNACIPRAN (Fetzima) Fact Sheet - Medication Fact Book ..., accessed October 2, 2025, https://www.thecarlatreport.com/ext/resources/factsheets/MFB7e/LEVOMILNACIPRAN-(Fetzima)-Fact-Sheet.pdf?t=1701639082
6. Fetzima Extended-Release (Levomilnacipran) Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults - American Health & Drug Benefits, accessed October 2, 2025, https://www.ahdbonline.com/issues/2014/march-2014-volume-7-special-feature-fifth-annual-payers-guide-to-new-fda-approvals/fetzima-extended-release-levomilnacipran-receives-fda-approval-for-the-treatment-of-major-depressive-disorder-in-adults
7. Milnacipran - Wikipedia, accessed October 2, 2025, https://en.wikipedia.org/wiki/Milnacipran
8. Levomilnacipran for the treatment of major depressive disorder - MDEdge, accessed October 2, 2025, https://ma1.mdedge.com/content/levomilnacipran-treatment-major-depressive-disorder
9. Levomilnacipran for the treatment of major depressive disorder: a review - PMC, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4295915/
10. Drug Approval Package: Brand Name (Generic Name) NDA # - accessdata.fda.gov, accessed October 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204168Orig1s000TOC.cfm
11. Fetzima (levomilnacipran) FDA Approval History - Drugs.com, accessed October 2, 2025, https://www.drugs.com/history/fetzima.html
12. Levomilnacipran Extended Release: First Global Approval - ResearchGate, accessed October 2, 2025, https://www.researchgate.net/publication/256378170_Levomilnacipran_Extended_Release_First_Global_Approval
13. Generic Fetzima Availability - Drugs.com, accessed October 2, 2025, https://www.drugs.com/availability/generic-fetzima.html
14. Levomilnacipran | CAS No- 96847-54-0 | L-Milnacipran ; (1S-cis) - Chemicea, accessed October 2, 2025, https://chemicea.com/product/levomilnacipran
15. Chemical structure of Levomilnacipran (LVM): (1S, 2R)-rel-2-(aminomethyl), accessed October 2, 2025, https://www.researchgate.net/figure/Chemical-structure-of-Levomilnacipran-LVM-1S-2R-rel-2-aminomethyl_fig1_236054065
16. Levomilnacipran - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed October 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK500639/
17. [Table, CHEMICAL FORMULAS AND STRUCTURES]. - LiverTox - NCBI Bookshelf, accessed October 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK547960/table/MilnacipranLevomilna.T3/
18. Compound: LEVOMILNACIPRAN (CHEMBL99946) - ChEMBL - EMBL-EBI, accessed October 2, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL99946
19. levomilnacipran - Drug Central, accessed October 2, 2025, https://drugcentral.org/drugcard/4864
20. go.drugbank.com, accessed October 2, 2025, https://go.drugbank.com/drugs/DB08918#:~:text=The%20exact%20mechanism%20of%20the,at%20serotonin%20and%20norepinephrine%20transporters.
21. Levomilnacipran (oral route) - Side effects & dosage - Mayo Clinic, accessed October 2, 2025, https://www.mayoclinic.org/drugs-supplements/levomilnacipran-oral-route/description/drg-20061242
22. Effect of renal impairment on the pharmacokinetics of ..., accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4485797/
23. Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study - Psychiatrist.com, accessed October 2, 2025, https://www.psychiatrist.com/jcp/efficacy-safety-levomilnacipran-sustained-release-major-depressive-disorder-phase-3-rct/
24. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review - PMC - PubMed Central, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4825949/
25. Levomilnacipran (Fetzima) for Major Depressive Disorder - AAFP, accessed October 2, 2025, https://www.aafp.org/afp/2015/1015/p727.pdf
26. Fetzima Side Effects: Common, Severe, Long Term - Drugs.com, accessed October 2, 2025, https://www.drugs.com/sfx/fetzima-side-effects.html
27. Label for FETZIMA (levomilnacipran) extended-release capsules - accessdata.fda.gov, accessed October 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204168s004lbl.pdf
28. Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1. - DrugBank, accessed October 2, 2025, https://go.drugbank.com/articles/A175957
29. Milnacipran - LiverTox - NCBI Bookshelf, accessed October 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK547960/
30. Fetzima (levomilnacipran) dosing, indications, interactions, adverse effects, and more, accessed October 2, 2025, https://reference.medscape.com/drug/fetzima-levomilnacipran-999862
31. Fetzima Dosage Guide - Drugs.com, accessed October 2, 2025, https://www.drugs.com/dosage/fetzima.html
32. Levomilnacipran Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed October 2, 2025, https://www.drugs.com/dosage/levomilnacipran.html
33. Studies - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed October 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204168s011lbl.pdf
34. FETZIMA® (levomilnacipran) ER Capsules, accessed October 2, 2025, https://www.fetzima.com/
35. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study - PubMed, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/23656841/
36. TGA rejects Fetzima - MAESTrO database, accessed October 2, 2025, https://maestrodatabase.com/blog/tga-rejects-fetzima
37. Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study - PMC, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4079528/
38. Australian Public Assessment Report for Levomilnacipran (as hydrochloride) - Therapeutic Goods Administration (TGA), accessed October 2, 2025, https://www.tga.gov.au/sites/default/files/auspar-levomilnacipran-161213.pdf
39. www.thecarlatreport.com, accessed October 2, 2025, https://www.thecarlatreport.com/ext/resources/factsheets/MFB7e/LEVOMILNACIPRAN-(Fetzima)-Fact-Sheet.pdf?t=1701639082#:~:text=Off%2DLabel%20Uses%3A%20Fibromyalgia%3B,peripheral%20neuropathy%3B%20chronic%20musculoskeletal%20pain.
40. Levomilnacipran: Package Insert / Prescribing Information - Drugs.com, accessed October 2, 2025, https://www.drugs.com/pro/levomilnacipran.html
41. Fetzima (levomilnacipran): Side effects, dosages, and more - MedicalNewsToday, accessed October 2, 2025, https://www.medicalnewstoday.com/articles/drugs-fetzima
42. Levomilnacipran.pdf - National Alliance on Mental Illness (NAMI), accessed October 2, 2025, https://www.nami.org/NAMI/media/NAMI-Media/Research/Levomilnacipran.pdf
43. Fetzima - VHB-master-uspi-levomilnacipran - 20085454 - 4-2024 - RxAbbVie, accessed October 2, 2025, https://www.rxabbvie.com/pdf/fetzima_pi.pdf
44. FETZIMA (levomilnacipran) - [Product Monograph Template - Standard], accessed October 2, 2025, https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/FETZIMA_PM_EN.pdf
45. fetzima-monograph.pdf - Canada's Drug Agency, accessed October 2, 2025, https://www.cda-amc.ca/sites/default/files/cdr/monograph/fetzima-monograph.pdf
46. Levomilnacipran Interactions - Drugs.com, accessed October 2, 2025, https://www.drugs.com/drug-interactions/levomilnacipran.html
47. Levomilnacipran (Fetzima) | National Alliance on Mental Illness (NAMI), accessed October 2, 2025, https://www.nami.org/about-mental-illness/treatments/mental-health-medications/types-of-medication/levomilnacipran-fetzima/
48. Levomilnacipran: MedlinePlus Drug Information, accessed October 2, 2025, https://medlineplus.gov/druginfo/meds/a613048.html
49. Fetzima Interactions: Alcohol, Supplements, and More - Healthline, accessed October 2, 2025, https://www.healthline.com/health/drugs/fetzima-interactions
50. Fetzima Food, Alcohol, Supplements and Drug Interactions - ScriptSave WellRx, accessed October 2, 2025, https://www.wellrx.com/fetzima/lifestyle-interactions/
51. FDA Approves Fourth SNRI to Treat Depression - Consultant360, accessed October 2, 2025, https://www.consultant360.com/exclusive/fda-approves-fourth-snri-treat-depression
52. AusPAR: Levomilnacipran (as hydrochloride) | Therapeutic Goods Administration (TGA), accessed October 2, 2025, https://www.tga.gov.au/resources/auspar/auspar-levomilnacipran-hydrochloride